AIMS/HYPOTHESIS: The aim of this study was to construct a model for predicting CHD and cardiovascular disease (CVD) risk in patients with newly diagnosed type 2 diabetes in a southern European region. External validation of two other cardiovascular risk models and internal validation of our model were assessed. METHODS: We studied 65,651 people attending a primary care setting in the Basque Country Health Service. A 10-year prospective population-based cohort study was performed with 777 patients newly diagnosed with type 2 diabetes older than 24 years in a Sentinel Practice Network. Cardiovascular risk factors, CVD events and mortality were registered. Coefficients for the significant predictors of CHD and CVD were estimated using Cox models. We assessed the discrimination and calibration of the UK Prospective Diabetes Study risk engine (UKPDS-RE), the Framingham Risk Score-Regicor Study (FRS-RS) and the cardiovascular risk model we developed. RESULTS: The incidence rate per 1,000 patients/year was calculated for microvascular and cardiovascular complications, and death. Age, the ratio of non-HDL- to HDL-cholesterol, HbA1c, systolic blood pressure and smoking were significant predictors of cardiovascular events. A risk model was developed using these predictors. The UKPDS-RE and FRS-RS showed inadequate discrimination (Uno's C statistics 0.62 and 0.58, respectively) and calibration (24% overestimation and 51% underestimation, respectively) for predicting CHD risk. The internal discrimination and calibration of the developed model were acceptable for predicting fatal/non-fatal 2- and 5-, but not 10-year CHD and CVD risk. CONCLUSIONS/ INTERPRETATION: This study is the first southern European validated population-derived model for predicting 5-year fatal/non-fatal CHD and CVD risk in patients with newly diagnosed type 2 diabetes.
AIMS/HYPOTHESIS: The aim of this study was to construct a model for predicting CHD and cardiovascular disease (CVD) risk in patients with newly diagnosed type 2 diabetes in a southern European region. External validation of two other cardiovascular risk models and internal validation of our model were assessed. METHODS: We studied 65,651 people attending a primary care setting in the Basque Country Health Service. A 10-year prospective population-based cohort study was performed with 777 patients newly diagnosed with type 2 diabetes older than 24 years in a Sentinel Practice Network. Cardiovascular risk factors, CVD events and mortality were registered. Coefficients for the significant predictors of CHD and CVD were estimated using Cox models. We assessed the discrimination and calibration of the UK Prospective Diabetes Study risk engine (UKPDS-RE), the Framingham Risk Score-Regicor Study (FRS-RS) and the cardiovascular risk model we developed. RESULTS: The incidence rate per 1,000 patients/year was calculated for microvascular and cardiovascular complications, and death. Age, the ratio of non-HDL- to HDL-cholesterol, HbA1c, systolic blood pressure and smoking were significant predictors of cardiovascular events. A risk model was developed using these predictors. The UKPDS-RE and FRS-RS showed inadequate discrimination (Uno's C statistics 0.62 and 0.58, respectively) and calibration (24% overestimation and 51% underestimation, respectively) for predicting CHD risk. The internal discrimination and calibration of the developed model were acceptable for predicting fatal/non-fatal 2- and 5-, but not 10-year CHD and CVD risk. CONCLUSIONS/ INTERPRETATION: This study is the first southern European validated population-derived model for predicting 5-year fatal/non-fatal CHD and CVD risk in patients with newly diagnosed type 2 diabetes.
Authors: Jaume Marrugat; Pascual Solanas; Ralph D'Agostino; Lisa Sullivan; José Ordovas; Ferran Cordón; Rafael Ramos; Joan Sala; Rafael Masià; Izabella Rohlfs; Roberto Elosua; William B Kannel Journal: Rev Esp Cardiol Date: 2003-03 Impact factor: 4.753
Authors: Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb Journal: Eur Heart J Date: 2013-08-30 Impact factor: 29.983
Authors: M Mata-Cases; C De Prado-Lacueva; V Salido-Valencia; E Fernández-Bertolín; J Casermeiro-Cortés; M García-Durán; S Jabalera-López; M I Fernández-Sanmartín Journal: Int J Clin Pract Date: 2011-03 Impact factor: 2.503
Authors: Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden Journal: Ann Intern Med Date: 2004-09-21 Impact factor: 25.391
Authors: Gary S Collins; Joris A de Groot; Susan Dutton; Omar Omar; Milensu Shanyinde; Abdelouahid Tajar; Merryn Voysey; Rose Wharton; Ly-Mee Yu; Karel G Moons; Douglas G Altman Journal: BMC Med Res Methodol Date: 2014-03-19 Impact factor: 4.615
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: X Shao; H Liu; F Hou; Y Bai; Z Cui; Y Lin; X Jiang; P Bai; Y Wang; Y Zhang; C Lu; H Liu; S Zhou; P Yu Journal: J Endocrinol Invest Date: 2022-08-16 Impact factor: 5.467
Authors: Antonio Rodriguez-Poncelas; Gabriel Coll-de-Tuero; Marc Saez; José M Garrido-Martín; José M Millaruelo-Trillo; Joan Barrot de-la-Puente; Josep Franch-Nadal Journal: BMC Cardiovasc Disord Date: 2015-10-13 Impact factor: 2.298
Authors: Domingo Orozco-Beltran; Vicente F Gil-Guillen; Josep Redon; Jose M Martin-Moreno; Vicente Pallares-Carratala; Jorge Navarro-Perez; Francisco Valls-Roca; Carlos Sanchis-Domenech; Antonio Fernandez-Gimenez; Ana Perez-Navarro; Vicente Bertomeu-Martinez; Vicente Bertomeu-Gonzalez; Alberto Cordero; Manuel Pascual de la Torre; Jose L Trillo; Concepcion Carratala-Munuera; Salvador Pita-Fernandez; Ruth Uso; Ramon Durazo-Arvizu; Richard Cooper; Gines Sanz; Jose M Castellano; Juan F Ascaso; Rafael Carmena; Maria Tellez-Plaza Journal: PLoS One Date: 2017-10-18 Impact factor: 3.240
Authors: Y K Chang; L F Huang; S J Shin; K D Lin; K Chong; F S Yen; H Y Chang; S Y Chuang; T J Hsieh; C A Hsiung; C C Hsu Journal: Sci Rep Date: 2017-10-04 Impact factor: 4.379
Authors: M A Salinero-Fort; F J San Andrés-Rebollo; J Cárdenas-Valladolid; M Méndez-Bailón; R M Chico-Moraleja; E Carrillo de Santa Pau; I Jiménez-Trujillo; I Gómez-Campelo; C de Burgos Lunar; J M de Miguel-Yanes Journal: Sci Rep Date: 2021-07-27 Impact factor: 4.379